Targeting and exploiting cytomegalovirus for vaccine development

Panagioti, E.

ABBREVIATIONS

Ad	Adenovirus
AICD	Activation-Induced Cell Death
APCs	Antigen Presenting Cells
CTL	Cytotoxic T lymphocyte
CCMV	Chimpanzee CMV
CMV	Cytomegalovirus
DC	Dendritic Cell
GPCMV	Guinea Pig CMV
HCMV	Human CMV
HIV	Human Immunodeficiency Virus
HLA	Human Leukocyte Antigen
HPV	Human Papilloma Virus
IE1	Immediate Early 1 protein
IE2	Immediate-Early 2 protein
IFN-γ	Interferon-γ
IL-2	Interleukin-2
IL-4	Interleukin-4
IL-12	Interleukin-12
MCMV	Mouse CMV
MHC	Major Histocompatibility Complex
MVA	Modified Vaccinia Ankara
NK cells	Natural killer cells
PAMPs	Pathogen-Associated Molecular Patterns
PBMCs	Peripheral Blood Mononuclear Cells
PCD	Programmed Cell Death
PFU	Plaque-Forming Units
pp65	protein 65
PRRs	Pattern Recognition Receptors
RCMV	Rat CMV
RhCMV	Rhesus CMV
SIV	Simian Immunodeficiency Virus
SLP	Synthetic Long Peptide
T_{CM}	Central Memory
T_{EM}	Effector Memory
T_{RM}	Tissue-Resident Memory
TNF	Tumor Necrosis Factor

CURRICULUM VITAE

Eleni Panagioti was born in 11 September 1988 in Athens, Greece. In 2011 she obtained first class bachelor degree in Biomedical Sciences from the University of Athens and then moved to England to pursue a Master's in Immunology and Immunogenetics at the University of Manchester. During her Master's she undertook an internship at the Immunology group of the Cancer research UK, Manchester Institute under the supervision of Prof. Peter Stern and Dr. David Gilham to characterize the functional properties of novel h5T4 monoclonal antibodies in malignant melanoma. In June 2013, she started a PhD on a prestigious Marie Curie Early Stage Research Fellowship, funded by the European Commission at the Department of Medical Oncology, at the Leiden University Medical Center under the supervision of Prof. Sjoerd van der Burg and Dr. Ramon Arens. During her fellowship, she received an excellent training in Vaccinology from world's leading universities and pharmaceutical companies.

LIST OF PUBLICATIONS

Beyranvand Nejad, E., **Panagioti, E.,** Redeker, A., Cicin-Sain L., van der Burg, S.H., and Arens, R. The level of pre-existing immunity determines the efficacy of MCMV-based vaccine vectors. *(in preparation*)

Panagioti, E., Klenerman, P., van der Burg, S.H., and Arens, R. Requirements for effective T cell-inducing vaccines against chronic viral infections. *(submitted)*

Panagioti, E., Lourens I.A., Eshan, I., Drijfhout, J.W., Welters, M.J., Arens, R., and van der Burg, S.H. The spontaneous response to Human Cytomegalovirus immediate early protein 2 is focused on 5 highly immunogenic regions and predominantly comprises polyfunctional type 1 $CD4^+$ T cells. *(submitted)*

Vanheusden, M., Broux, B., Welten, S. P., Peeters, L. M., **Panagioti, E.,** Van Wijmeersch, B., Somers, V., Stinissen, P., Arens, R., and Hellings, N. 2017. Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation. *Scientific Reports* 7:663.

Panagioti, E., Boon, L., Arens, R., and van der Burg, S. H. 2017. Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective $CD4^+$ and $CD8^+$ T Cell Responses against Mouse Cytomegalovirus Infection. *Frontiers in Immunology* 8:144.

Panagioti, E., Redeker, A., van Duikeren, S., Franken, K. L., Drijfhout, J. W., van der Burg, S. H., and Arens, R. 2016. The Breadth of Synthetic Long Peptide Vaccine-Induced $CD8^+$ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection. *PLoS Pathogens* 12: e1005895.

AKNOWLEDGEMENTS

In this part, I would like to acknowledge a number of individuals whose help was critical for the completion of this research.

First and foremost, I would like to express my deep gratitude to my supervisors, Prof. Sjoerd van der Burg and Dr. Ramon Arens since without their support I would not have been able to complete this thesis. Sjoerd thank you for inputting your wisdom and longstanding experience into this piece of research and for your invaluable guidance, on-going productive feedback and motivation. Ramon, thank you for your scientific ideas, encouragement and for enhancing my research development.

Thanks to my student Ierry-Ann for her precious assistance with the study pertaining to Chapter 4 of this thesis and everyone who supported this research. Thanks to all my office mates (Bianca, Marjolein, Marteen, Vanessa, Nikki, Ilina, Renske, Linda, Wenbo, Koen, Elien, Elham and Ferenc) for providing a stimulating academic and social environment. Thanks to my lunchmates Wenbo, Marcel, Hreinn, Heng Sheng and Junling for all the joyful moments that we shared. Thanks to all the members of the Medical Oncology and Tumour Immunology departments for the research discussions and scientific feedback.

It is also important to say an endless "thank you" to my mum, dad and sister, for their unconditional love, trust, encouragement and patience. Μαμά, μπαμπά και αδερφούλα σας ευχαριστώ πάρα πολύ για την άνευ όρων αγάπη, στήριξη και υπομονή που μου δείξατε όλα αυτά τα χρόνια! Thanks also to Roberta, Alexia, Wenbo, Dimitri, Giorgo, Zhenia, Kristina, Eirini and George for their honest friendship, pleasant company and for generously offering their understanding and support at times of stress.

Finally, I would like to thank the VacTrain network team for offering me outstanding training experience and fun.